Sundance Diagnostics
Sundance Diagnostics develops advanced genetic safety tests to predict patient risks and improve drug safety.
Founded
2012Sundance Diagnostics develops advanced genetic safety tests to predict patient risks and improve drug safety.
Founded with the mission to enhance pharmaceutical safety, Sundance Diagnostics focuses on developing genetic safety tests to predict patients' risks of antidepressant-induced suicidal thoughts or behaviors. Utilizing cutting-edge genetic technologies, the company aims to save lives, improve treatment outcomes, and increase overall drug safety. Their primary market includes healthcare providers and pharmaceutical companies seeking to mitigate the severe side effects associated with antidepressant medications.
Sundance Diagnostics has garnered attention from notable figures in the medical and biotech fields and has attracted investment from key stakeholders committed to advancing genetic testing. The company's pioneering work in predictive genetic safety has positioned it as a leader in personalized medicine, contributing significantly to patient safety and the broader healthcare industry. Their innovative approach has the potential to revolutionize how mental health treatments are prescribed, ultimately reducing adverse effects and improving patient care.
Companies similar to Sundance Diagnostics include Juno Diagnostics, SureGene, Genetic Foresight and Heligenics.
Sundance Diagnostics was founded in 2012.
Sundance Diagnostics' headquarters is located in Grand Junction, CO, US.
Sundance Diagnostics' most recent funding round was for $5.5k (USD) in May 2015.
As of May 19, 2015, Sundance Diagnostics has disclosed funding of $6.5k (USD). Undisclosed round amounts are excluded.
Sundance Diagnostics has 6 employees as of Feb 5, 2024.
